QuorumCivic. Hidden in plain sight Get the app
Bill intelligence

Coast Guard gets naloxone mandate; Congress demands overdose data

H.R. 2351 — To direct the Commandant of the Coast Guard to update the policy of the Coast Guard regarding the use of medication to treat drug overdose, and for other purposes. · Filed by Addison McDowell (R-NC) · 2 cosponsors · Introduced Mar 26, 2025 · Passed chamber

75%
Transparency
Typical bill: 82%
15/100
Hidden-provision risk
Typical bill: 15/100
Public Health / Substance Abuse Mitigation

Your members of Congress

Enter a ZIP to see where your representative and both senators stood on this bill.

Looked up on this device — your ZIP is never stored on our servers.

What it does

This bill directs the Coast Guard to update its policy on naloxone (Narcan) and similar overdose-reversal medications, requiring these drugs be available at all Coast Guard installations and in operational environments. It also mandates the Coast Guard join a Defense Department tracking system for overdose incidents and report to Congress within two years on naloxone use, fentanyl prevalence, and substance-abuse mitigation efforts among Coast Guard personnel.

Why we flagged it

The bill's operative mechanism is a mandate to expand naloxone availability and reporting within the Coast Guard, framed as a public-health and personnel-safety measure. The opening amendments to maritime drug-trafficking statutes are technical clarifications, not the bill's primary purpose.

What the text implies

  • Mandatory participation in a DoD tracking system may create a permanent database of Coast Guard personnel overdose incidents, potentially affecting career advancement, security clearances, or medical discharge decisions if not carefully protected by privacy safeguards.
  • The bill requires naloxone availability 'in each operational environment,' which may impose logistical and cost burdens on remote or maritime operations where supply chains are constrained.

The full analysis lists 3 implications of this text.

Who stands to gain

pharmaceutical manufacturers of naloxone and opioid-reversal medications (Amphastar, Adapt Pharma/Pu

Correlative observation from public records — not evidence of coordination or wrongdoing, and not financial advice.
This page is the record as of today. The app tells you when it changes.
Quorum analysis of the full bill text · 119th Congress · public record